Hao Zhou

Hao Zhou

Auto-generated profile, based on publicly available information

Hao Zhou

Department of Cardiology, West China Hospital, Sichuan University, 610041 Chengdu, Sichuan, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
HZHao Zhou
Hao Zhou
TLTing Liu
Ting Liu
FLFuxia Lan
Fuxia Lan
KLKai Liu
Kai Liu
XWXin Wei
Xin Wei
YXYing Xu
Ying Xu
Background: The clinical value of B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided therapy for improving outcomes in patients with heart failure (HF) remains controversial. Thus, this meta-analysis synthesizes the available evidence from randomized controlled trials (RCTs) to determine whether a biomarker-guided strategy reduces all-cause mortality and HF-related hospitalizations compared with clinically guided management. Methods: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We conducted a systematic search of PubMed, Embase, the Cochrane Library, and Web of Science databases from inception to May 2025 for RCTs comparing biomarker-guided versus clinically guided management in patients with HF. Pooled risk ratios (RRs) were calculated using a random-effects model. We performed extensive supplementary analyses, including a subgroup analysis, sensitivity analysis, and trial sequential analysis (TSA). Results: We included 17 articles (reporting on 17 distinct RCTs) comprising 5069 patients. The primary meta-analysis showed that biomarker-guided therapy was associated with a significant reduction in all-cause mortality (RR 0.84, 95% confidence interval (CI) 0.73–0.96; I2 = 12.2%) and HF-related hospitalizations (RR 0.79, 95% CI 0.65–0.96; I2 = 53.7%). However, the robustness of these findings was undermined by subsequent analyses. Meanwhile, a sensitivity analysis restricted to studies with a low risk of bias rendered the mortality benefit non-significant (RR 0.90, 95% CI 0.79–1.03). Egger's test indicated potential publication bias (p = 0.0285), and TSA suggested the cumulative evidence was insufficient to draw a definitive conclusion. Conclusions: Although there is a trend toward benefit, the existing evidence for biomarker-guided HF therapy is deemed “very low” quality based on the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment. The results were compromised by methodological deficiencies in primary studies and potential publication bias. Therefore, the evidence is inadequate to support the routine use of this strategy in clinical practice. Further large-scale, high-quality RCTs are warranted. The PROSPERO Registration: CRD420250652134, https://www.crd.york.ac.uk/PROSPERO/view/CRD420250652134.

25 August 2025 in JMIR Preprints
Verified
Preprint
Open access
HZHao Zhou
Hao Zhou
TLTing Liu
Ting Liu
FLFuxia Lan
Fuxia Lan
KLKai Liu
Kai Liu
YXYing Xu
Ying Xu
XWXin Wei
Xin Wei
BACKGROUND Fluid overload in heart failure (HF) remains a critical driver of morbidity and mortality. Current guideline-directed fluid management strategies based on clinical signs and symptoms lack sensitivity for the early detection of congestion. This limitation often leads to delayed interventions or suboptimal fluid removal, contributing to high rates of rehospitalization and poor patient outcomes. Biomarker-guided strategies, particularly using B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP), offer a potential solution by providing objective, real-time feedback on hemodynamic stress. OBJECTIVE This study aims to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of biomarker-guided fluid management compared to standard, clinically guided strategies in patients with HF. The primary objectives are to determine whether a biomarker-guided approach reduces all-cause mortality and HF-related hospitalizations. Secondary objectives include assessing the impact on renal function, quality of life, and changes in biomarker levels. METHODS We will conduct a systematic search of PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science from their inception to May 2025. We will include randomized controlled trials and prospective cohort studies that compare fluid management guided by BNP or NT-proBNP to clinically guided standard care in adult patients with HF. Two investigators will independently perform study selection, data extraction, and risk of bias assessment using the Cochrane Risk of Bias 2.0 (RoB 2) and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tools. The primary outcomes are all-cause mortality and HF-related hospitalizations. Secondary outcomes include worsening renal function, quality of life measured by validated questionnaires, and biomarker trajectory. Statistical analysis will be performed using RevMan 5.4. We will use a random-effects model for meta-analysis and conduct subgroup analyses based on HF phenotype (eg, reduced vs preserved ejection fraction) and biomarker type. RESULTS This study will synthesize the available evidence on the efficacy and safety of biomarker-guided fluid management in HF. The findings, based on outcomes such as mortality, hospitalization rates, renal function, and quality of life, will be submitted for publication in a peer-reviewed journal. CONCLUSIONS This systematic review will consolidate the current evidence for biomarker-guided fluid management in HF. The findings are expected to inform clinical guidelines and decision-making by providing a comprehensive assessment of the benefits and risks of this approach. Furthermore, this review will identify existing research gaps and suggest directions for future investigations to optimize fluid management strategies in this vulnerable patient population. CLINICALTRIAL PROSPERO CRD420250652134; https://www.crd.york.ac.uk/PROSPERO/view/CRD420250652134